VSIR and ovarian carcinoma: Expression of the immune checkpoint VISTA is associated with poor prognosis in pancreatic, breast, bladder, colorectal, and ovarian cancers, and drugs targeting VISTA are currently being developed for cancer treatment [12, 57, 58].